Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT

Table 1 ADEPT baseline demographics and disease severity characteristics

Characteristic	Placebo (n = 152)	Adalimumab 40 mg every other week (n = 144)
Age (years)^a	49.4 ± 11.1	47.8 ± 11.9
Male (%)	55.3	56.3
White (%)	94.1	97.2
Body weight (kg)^a	85.4 ± 16.4	86.1 ± 20.5
Psoriatic arthritis duration (years)^a	9.3 ± 8.8	9.9 ± 8.3
Psoriasis duration (years)^a	16.8 ±12.4	17.2 ± 12.1
Modified total Sharp score (0.5 (%)^b	16.4	11.8
Modified total Sharp score^a	20.0 ± 36.3	22.3 ± 46.6
Joint erosion score	10.5 ± 20.2	11.4 ± 25.9
Joint space narrowing score	9.5 ± 17.3	10.9 ± 21.8
CRP (0.287 mg/dl (%)^c	22.4	19.4
CRP (mg/dl)^a	1.4 ± 1.7	1.4 ± 2.1
Rheumatoid factor-negative (%)	90.1	89.6
Patients taking methotrexate at baseline (%)	51.3	51.4
Tender joint count (0 to 78 joints)^a	25.8 ± 17.9	23.6 ± 17.4
Swollen joint count (0 to 76 joints)^a	14.4 ± 11.4	13.6 ± 11.6
HAQ Disability Index (0 to 3)^a	1.0 ± 0.7	1.0 ± 0.6

HAQ, Health Assessment Questionnaire. P > 0.2 for all adalimumab vs. placebo. ^aMean ± standard deviation. ^bAbsence of radiographic progression, defined as modified total Sharp score ≤0.5. ^cNormal C-reactive protein (CRP) by high-sensitivity assay, defined as ≤0.287 mg/dl.

ISSN: 1478-6362